Dr. Byung Hee Yoo’s expertise lies in “theranostic cancer imaging.” His research has focused on quantitative visualization of biological/physiological events. Since reporting the first peptidyl MR contrast agents, he has developed a wide spectrum of additional imaging probes for the quantitation of proteomic/genomic biomarkers. His recent research has integrated RNA interference and nanomedicine for the inhibition of cancer progression by the regulation of oncogenic mRNA and miRNA in cancer cells. He is interested in the prevention of multi-drug resistance in chemotherapy and the monitoring of physiological parameters in a non-invasive manner.


PhD in Biomedical Engineering, Case Western Reserve University

Select Publications

1. Yoo B, Pagel MD. A PARACEST MRI contrast agent to detect enzyme activity. J Am Chem Soc. 2006 Nov 1;128(43):14032-3.

2. Chen J, Ratnayaka S, Alford A, Kozlovskaya V, Liu F, Xue B, Hoyt K, Kharlampieva E. Theranostic Multilayer Capsules for Ultrasound Imaging and Guided Drug Delivery. ACS Nano. 2017 Mar 28;11(3):3135-3146.

3. Yoo B, Meka N, Sheedy P, Billig AM, Pantazopoulos P, Medarova Z. MicroRNA-710 regulates multiple pathways of carcinogenesis in murine metastatic breast cancer. PLoS One. 2019 Dec 13;14(12):e0226356.


  • Nanoemulsion comprising metabolites of ginseng saponin as an active component and a method for preparing the same, and a skin-care composition for anti-aging containing the same. Patent US8263565.
  • Flexibly labeling peptides. Patent US8784777
  • Therapeutic microRNA compositions and methods of use. Patent pending (Medarova Z, Yoo B.)